This module uses fundamental data of Galmed Pharmaceuticals to approximate its Piotroski F score. Galmed Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Galmed Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Galmed Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Galmed Pharmaceuticals Altman Z Score, Galmed Pharmaceuticals Correlation, Galmed Pharmaceuticals Valuation, as well as analyze Galmed Pharmaceuticals Alpha and Beta and Galmed Pharmaceuticals Hype Analysis.
The current year's Net Debt To EBITDA is expected to grow to 0.43, whereas Short and Long Term Debt Total is forecasted to decline to about 39 K. At present, Galmed Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Book Value Per Share is expected to grow to 63.36, whereas Free Cash Flow Yield is projected to grow to (4.80).
At this time, it appears that Galmed Pharmaceuticals' Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Galmed Pharmaceuticals is to make sure Galmed is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Galmed Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Galmed Pharmaceuticals' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Galmed Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Galmed Pharmaceuticals in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
63.36
At present, Galmed Pharmaceuticals' Book Value Per Share is projected to increase significantly based on the last few years of reporting.
Galmed Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Galmed Pharmaceuticals from analyzing Galmed Pharmaceuticals' financial statements. These drivers represent accounts that assess Galmed Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Galmed Pharmaceuticals' important valuation drivers and their relationship over time.
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Galmed Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Galmed Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social
About Galmed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galmed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
69.72
Return On Assets
(0.29)
Return On Equity
(0.53)
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.